A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11.